How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

Table 5

Summary of characteristics of patients enrolled in SGLT2i CVOTs and of patients from the SIDIAP database that would have met the corresponding criteria.

Characteristics	EMPA-REG OUTCOME	CANVAS	DECLARE-TIMI 58	General population (SIDIAP database)
Drug	Empagliflozin	Canagliflozin	Dapagliflozin	Empagliflozin/canagliflozin/dapagliflozin
Participants,	7,020	10,142	17,160	373,185
Male (%)	71.5	64.2	62.6	54.9
Age (years), mean (SD)	63.1 (8.7)	63.3 (8.3)	63.9 (6.8)	70.1 (12.3)
Patients with established CVD, (%)	7,020 (>99)	6,656 (66)	6,974 (41)	EMPA-REG OUTCOME criteria: 86,534 (23.2); CANVAS criteria: 86,531 (23.2); DECLARE-TIMI 58 criteria: 86,468 (23.2)
CVRFs, (%)	—	3486 (34)	10,186 (59)	CANVAS criteria: 189,969 (50.9); DECLARE-TIMI 58 criteria: 289,126 (77.5)
HbA1c (%), mean (SD)	8.1 (0.8)	8.2 (0.9)	8.3 (1.2)	7.12 (1.32)
eGFR (ml/min/1.73 m^2), (%)
≥60	5,199 (74.1)	8,114 (79.9)	15,959 (92.6)	241,958 (72)
<60-30	1,819 (25.9)	2,028 (20.1)	1,201 (7.4)	80,978 (24)
<30	0	0	0	13,262 (4)

CVD: cardiovascular disease; CVRF: cardiovascular risk factors; eGFR: estimated glomerular filtration rate; SD: standard deviation; CVOTs: cardiovascular outcome trials.